Literature DB >> 10063876

Sonographic detection of uterine and ovarian abnormalities in female survivors of Wilms' tumor treated with radiotherapy.

A R Nussbaum Blask1, H S Nicholson, B M Markle, K Wechsler-Jentzch, R O'Donnell, J Byrne.   

Abstract

OBJECTIVE: The purpose of this study was to use sonography to evaluate the size of the ovaries and uterus in survivors of Wilms' tumor who underwent radiotherapy. SUBJECTS AND METHODS: Eighteen survivors of Wilms' tumor had their ovaries and uterus measured on sonography. Their ages at diagnosis and treatment ranged from 14 months to 6 years. Four girls were prepubertal (age, 5-9 years), 11 were postpubertal (age, 11-30 years), and three had primary ovarian failure (age, 15-23 years) at the time of imaging. Findings were compared with those of a control group of 25 prepubertal and 25 postpubertal girls and women. Gonadotropin levels were measured.
RESULTS: Three patients who underwent whole abdomen radiotherapy had elevated levels of gonadotropin and primary ovarian failure. Neither ovary was seen in two of the three patients and both ovaries were abnormally small (< or = 1 cm3) in the third patient. The uterus was abnormally small (length, < or = 4 cm) in all three of these patients even though two were being treated with hormone replacement therapy. Ten postpubertal patients who underwent hemiabdomen radiotherapy had normal gonadotropin levels and a normal-sized uterus on sonography; the ovary on the side that received radiotherapy was not seen in three of the 10 patients or was abnormally small (< or = 1.4 cm3) in two of the 10 patients compared with all normal ovaries in the postpubertal control group (p < .0001). One postpubertal patient with bilateral renal bed radiotherapy had normal ovaries and a normal-sized uterus. Significantly more patients in the postpubertal and ovarian failure radiotherapy group (5 [36%] of 14 patients) had one or both ovaries not seen than the control group (none [0%] of 25 patients; p = .0014). The uterus was significantly smaller than normal in three (23%) of the 13 patients in the postpubertal hemiabdomen and ovarian failure radiotherapy group versus none of the 25 patients in the postpubertal control group (p = .0339).
CONCLUSION: Postpubertal female survivors of Wilm's tumor who underwent radiotherapy as children may have one or two small or absent ovaries and a small uterus that can be detected by sonography. The response of the uterus to hormone replacement therapy can also be assessed on sonography.

Entities:  

Mesh:

Year:  1999        PMID: 10063876     DOI: 10.2214/ajr.172.3.10063876

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  Pregnancy outcomes among adult survivors of childhood cancer in the British Childhood Cancer Survivor Study.

Authors:  Raoul C Reulen; Maurice P Zeegers; W Hamish B Wallace; Clare Frobisher; Aliki J Taylor; Emma R Lancashire; Dave L Winter; Mike M Hawkins
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08       Impact factor: 4.254

Review 2.  Wilms tumour: prognostic factors, staging, therapy and late effects.

Authors:  Sue C Kaste; Jeffrey S Dome; Paul S Babyn; Norbert M Graf; Paul Grundy; Jan Godzinski; Gill A Levitt; Helen Jenkinson
Journal:  Pediatr Radiol       Date:  2007-11-17

Review 3.  Late effects of treatment for wilms tumor.

Authors:  Karen D Wright; Daniel M Green; Najat C Daw
Journal:  Pediatr Hematol Oncol       Date:  2009-09       Impact factor: 1.969

4.  White paper: Oncofertility in pediatric patients with Wilms tumor.

Authors:  M E Madeleine van der Perk; Nicholas G Cost; Annelies M E Bos; Robert Brannigan; Tanzina Chowdhury; Andrew M Davidoff; Najat C Daw; Jeffrey S Dome; Peter Ehrlich; Norbert Graf; James Geller; John Kalapurakal; Kathleen Kieran; Marcus Malek; Mary F McAleer; Elizabeth Mullen; Luke Pater; Angela Polanco; Rodrigo Romao; Amanda F Saltzman; Amy L Walz; Andrew D Woods; Marry M van den Heuvel-Eibrink; Conrad V Fernandez
Journal:  Int J Cancer       Date:  2022-05-11       Impact factor: 7.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.